0000899243-20-032050.txt : 20201124
0000899243-20-032050.hdr.sgml : 20201124
20201124173639
ACCESSION NUMBER: 0000899243-20-032050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201123
FILED AS OF DATE: 20201124
DATE AS OF CHANGE: 20201124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39712
FILM NUMBER: 201345577
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001750284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300409740
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
BUSINESS PHONE: (415) 651-3316
MAIL ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-23
1
0001750284
Olema Pharmaceuticals, Inc.
OLMA
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
Common Stock
2020-11-23
4
C
0
1273420
A
1273420
D
Common Stock
2020-11-23
4
C
0
451986
A
1725406
D
Series B Preferred Stock
2020-11-23
4
C
0
1273420
0.00
D
Common Stock
1273420
0
D
Series C Preferred Stock
2020-11-23
4
C
0
451986
0.00
D
Common Stock
451986
0
D
Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date.
Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Advisor, /s/ Peter McIsaac, Title: Authorized Person
2020-11-23